VRAX
NASDAQ
$3.89
Virax Biolabs Group Ltd - Class A (VRAX)
Virax Biolabs Group Limited, a biotechnology company, sells, distributes and markets diagnostic test kits and medical technology products and PPE for the prevention, detection, diagnosis and risk management of viral diseases in the field of immunology. The company is headquartered in London, the United Kingdom.
Sector:
Healthcare
Industry:
Biotechnology
Target: $25 (+542.67%)
Market Cap
$1.52M
P/B Ratio
0.42
Beta (5Y)
1.14
Price Chart
Valuation
Market Cap$1.52M
P/S793.06
P/B0.42
Profitability
Total Revenue (TTM)$88K
Gross Profit (TTM)$7.69K
EBITDA-$12M
Operating Margin-160788%
EPS-$3.85
Financial Health
Debt-to-Equity10.1%
Growth & Risk
Beta (5Y)1.14
Sharpe Ratio-0.20